VERTIGO TREATMENTS MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024 - 2031)

Regional Analysis

To learn more about this report, Request sample copy

Dominating Region: North America

North America dominates the vertigo treatments market with an estimated share of 38.2% in 2024. This can be attributed to factors such as the well-established healthcare infrastructure and high healthcare expenditure. The region is home to many leading biopharmaceutical companies like Johnson & Johnson focusing on neurological disorders. Supportive government policies have promoted R&D investments in novel therapeutic areas.

Fastest-Growing Region: Asia Pacific

The Asia Pacific market exhibits the fastest growth, driven by rising awareness about balance disorders and an increasing aging population. Countries like China and India are witnessing rapid economic expansion and improving access to healthcare. Local companies are contributing through generics and biosimilars to meet the large unmet needs.

Vertigo Treatments Market Outlook for Key Countries

Rising Benign Paroxysmal Positional Vertigo in the U.S.

The U.S. vertigo treatments market is significantly driven by the rising incidence of benign paroxysmal positional vertigo and adoption of innovative technologies. In February 2022, according to an article in the National Library of Medicine, benign paroxysmal positional vertigo (BPPV) has an annual incidence of 64 per 100,000 individuals in the U.S. This rate increases by 38% with each advancing decade, resulting in over 200,000 new cases nationwide each year.

Growth Reflecting Rising Incomes in China

China's vertigo treatments industry growth for treating peripheral vertigo reflects rising disposable incomes and an increased focus on neurological conditions. In July 2024, China's National Health Commission reported that over 20 million people in China suffer from vertigo-related symptoms, creating a substantial market opportunity. A local company, Yuhuang Pharmaceutical, successfully launched affordable treatment options in February 2024, contributing to improved access for patients.

Japan’s Leading Position in Pharmaceutical Development in Japan

Japan continues to excel in pharmaceutical development, benefiting from its advanced research ecosystem. In October 2022, the National Library of Medicine reported that Japan has one of the highest rates of Meniere's disease diagnoses globally, with approximately 1.5 million cases. Company Eisai Co., Ltd. is at a frontrunner in developing innovative treatments for Meniere's disease, having launched a new drug in January 2024 that targets specific symptoms associated with the condition.

Expanding Healthcare Access in India

India's vertigo treatments industry for vestibular disorder treatments is supported by its large population and a focus on expanding healthcare access in both urban and rural areas. On October 12, 2024, Government Rajaji Hospital (GRH) in Madurai, India inaugurated an advanced vertigo lab, marking a significant milestone as the first government hospital in Tamil Nadu, India to introduce such a facility.